A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2004
11/11/2004	US20040223975 Methods for treating cardiovascular diseases with botulinum toxin
11/11/2004	US20040223974 Vaccines, immunotherapeutics and methods for using the same
11/11/2004	US20040223969 modulating tumor growth by contacting a tumor cell with an agonist or antagonist of IL-23, particularly a binding mixture of IL-23R or nucleotide coding it comprising: an antigen-binding site of an antibody; an extracellular region of IL-23R; a small molecule; and an anti-sense nucleic acid or siRNA
11/11/2004	US20040223968 inhibiting a condition characterized by monocytic infiltrates such as atherosclerosis by administering an MCP-1 receptor antagonist that binds to an MCP-1 receptor polypeptide, especially a humanized or monoclonal antibody.
11/11/2004	US20040223966 inhibiting growth and differentiation factor-8 activity; diagnosing, preventing, or treating degenerative disorders of muscle, bone, or glucose homeostasis.
11/11/2004	US20040223965 Hepatitis b core antigen fusion proteins
11/11/2004	US20040223964 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/11/2004	US20040223963 Method for treating ischemic stroke with melatonin
11/11/2004	US20040223962 administering a combination of a fibrinolytic agent and an antioxidant; particularly useful for treating individuals prior to or during long term flights or other situations involving extended immobility.
11/11/2004	US20040223961 Enzyme treatment
11/11/2004	US20040223960 lipid hydrolyzing protein or polypeptide, particularly the protein lysosomal acid lipase; treating atherosclerosis, Wolman's Disease and Cholesteryl Ester Storage Disease
11/11/2004	US20040223958 Glutathione reductase for therapy and prophylaxis of AIDS
11/11/2004	US20040223953 Combined adeno-associated virus and adenovirus cocktail gene delivery system for high efficiency gene expression without eliciting immune response in immuno-competent subjects
11/11/2004	US20040223952 Generation and/or reduction of new lung tissue in an affected lung
11/11/2004	US20040223951 temozolomide is administered on a daily basis and pegylated interferon alpha is administered on a weekly basis.
11/11/2004	US20040223950 the bond to the IFN-alpha 2a is at a lysine residue; isolation using liquid chromatography; prophylaxis of viral or immunomodulatory diseases, especially for the treatment of viral diseases
11/11/2004	US20040223948 Drug-oligomer conjugates with polyethylene glycol components
11/11/2004	US20040223917 Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
11/11/2004	DE10317369A1 proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen proNGF as pharmaceutically active agents for treating demyelinating diseases
11/11/2004	CA2847490A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
11/11/2004	CA2847486A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
11/11/2004	CA2525488A1 Extraction process for a pharmaceutical product
11/11/2004	CA2524573A1 Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
11/11/2004	CA2524270A1 Method for the production of an n-terminally modified chemotactic factor
11/11/2004	CA2524253A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
11/11/2004	CA2524071A1 Toll-like receptor 9 effector agents and uses thereof
11/11/2004	CA2523830A1 Methods and compositions using gonadotropin hormone releasing hormone
11/11/2004	CA2523600A1 Methods utilising g-protein coupled receptor 54
11/11/2004	CA2523579A1 Biological pacemaker
11/11/2004	CA2523576A1 Preventives or remedies for hepatopathy
11/11/2004	CA2523575A1 Genetic modification of targeted regions of the cardiac conduction system
11/11/2004	CA2523573A1 Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
11/11/2004	CA2523539A1 Production of high mannose proteins in plant culture
11/11/2004	CA2523517A1 Bcl2l12 polypeptide activators and inhibitors
11/11/2004	CA2523508A1 Galectin 9-inducing factors
11/11/2004	CA2523432A1 Solid drug formulation and device for storage and controlled delivery thereof
11/11/2004	CA2523402A1 Group 1 mite polypeptide variants
11/11/2004	CA2523363A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
11/11/2004	CA2523357A1 Treatment of hi-virus infections with oxidised blood proteins
11/11/2004	CA2523341A1 Compositions and methods for treatment of psoriasis
11/11/2004	CA2523025A1 Spex compositions and methods of use
11/11/2004	CA2523022A1 Nogo-b, a regulator of endothelial cell function and vessel remodeling
11/11/2004	CA2522895A1 Combined use of keratinocyte growth factor agonists and gastrin compounds
11/11/2004	CA2522890A1 Method for selective inhibition of human n-myc gene in n-myc expressing tumors through anti-sense and sense peptide nucleic acids
11/11/2004	CA2522868A1 Vector comprising gastric protection for oral administration
11/11/2004	CA2522833A1 Saposin c-dops: a novel anti-tumor agent
11/11/2004	CA2522460A1 Beta-amyloid inhibitors and use thereof
11/11/2004	CA2522263A1 Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure oftarget protein, sustained-release preparation and method of producing antibody against target protein
11/11/2004	CA2522108A1 Secreted protein family
11/11/2004	CA2521735A1 Fast dissolving orally consumable films containing a sucralose as a sweetener
11/11/2004	CA2521624A1 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem
11/11/2004	CA2521560A1 Hsa-free stabilized interferon liquid formulations
11/11/2004	CA2520959A1 Catalyst for cleaving sugar chain
11/11/2004	CA2520243A1 Pharmaceutical compositions for treating painful neuropathy and methods of treating same
11/11/2004	CA2518776A1 Insulin analogs having protracted time action
11/11/2004	CA2511353A1 Solid dosage form comprising desmopressin and method for manufacturing thereof
11/10/2004	EP1475639A2 Tumour-specific P450 protein
11/10/2004	EP1475442A2 Polypeptides of feline T-cell lymphotropic lentivirus
11/10/2004	EP1475440A2 Growth differentiation factor-3
11/10/2004	EP1475114A2 Injection system suitable for the administration of semisolid, sustained-release pharmaceutical compositions of gelable peptide salts
11/10/2004	EP1475104A1 Stabilized proteinic preparation
11/10/2004	EP1475099A1 Use of botulinum toxin to treat urinary incontinence
11/10/2004	EP1475098A1 High-concentration preparation of soluble thrombomodulin
11/10/2004	EP1474535A2 Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
11/10/2004	EP1474516A2 Methods of modulating cold sensory perception
11/10/2004	EP1474512A2 Method to modify differentiation of pluripotential stem cells
11/10/2004	EP1474510A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
11/10/2004	EP1474506A2 Cytochrome p450 protein
11/10/2004	EP1474505A1 Vaccination and vaccine and drug delivery by topical application of vectors and vector extracts recombinant vectors, and noninvasive genetic immunization, expression products therefrom,and uses thereof
11/10/2004	EP1474451A2 De-immunized (poly)peptide constructs
11/10/2004	EP1474448A1 Rrp sequences and knockout mice and uses thereof
11/10/2004	EP1474447A2 Antigens for immunocontraception
11/10/2004	EP1474446A2 Mhc class ii peptide epitope of 5t4 antigen
11/10/2004	EP1474445A1 Glycoisoforms of adiponectin and uses thereof
11/10/2004	EP1474444A1 A novel splice variant of myd88 and uses thereof
11/10/2004	EP1474443A1 Tolerogenic peptides from myelin basic protein
11/10/2004	EP1474442A2 Cytotoxic t-cell epitopes from chlamydia
11/10/2004	EP1474441A1 Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
11/10/2004	EP1474440A2 Coniosulphides and their derivatives, method for their production and use as medicaments
11/10/2004	EP1474439A2 Dipeptides and tripeptides with anti-inflammatory activity
11/10/2004	EP1474438A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
11/10/2004	EP1474433A2 RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA)
11/10/2004	EP1474423A1 Heterocyclic tripeptides as hepatitis c inhibitors
11/10/2004	EP1474176A2 Novel human g-protein coupled receptor, hgprbmy31, and variants and methods of use thereof
11/10/2004	EP1474172A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors
11/10/2004	EP1474169A2 Means and methods for altering the motility of the gastrointestinal tract
11/10/2004	EP1474167A2 Novel proteins in enteroaggregative esheriachia coli (eaec) useful for diagnosis and therapy of eaec infections
11/10/2004	EP1474164A2 Use of amylin agonists to modulate triglycerides
11/10/2004	EP1474163A2 Modification of feeding behavior
11/10/2004	EP1474162A1 Methods and compositions for the treatment of eye diseases
11/10/2004	EP1474158A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
11/10/2004	EP1474156A2 Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors
11/10/2004	EP1474144A1 Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
11/10/2004	EP1474128A2 S−DIMETHYLARSINO−THIOSUCCINIC ACID S−DIMETHYLARSINO−2−THIOBENZOIC ACID S−(DIMETHYLARSINO) GLUTATHIONE AS TREATMENTS FOR CANCER
11/10/2004	EP1474096A2 Methods and compositions for the promotion of hair growth utilizing actin binding peptides
11/10/2004	EP1474093A2 Granzyme b inhibitors
11/10/2004	EP1265570B1 Soluble keratin peptide
11/10/2004	EP1028745A4 Interferon immunotherapy
11/10/2004	EP1012280B1 Trimerising module
11/10/2004	EP0986754A4 Synthetic antibiotics

1 ... 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 ... 3163